FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800100422> ?p ?o ?g. }

• W2800100422 endingPage "2359" @default.
• W2800100422 startingPage "2354" @default.
• W2800100422 abstract "Background The antiplatelet drug cilostazol decreases the risk of ischemic stroke recurrence in patients with chronic cerebral infarction. Additionally, cilostazol reduces the occurrence of pneumonia in these patients. The purpose of this study was to investigate whether cilostazol is effective for preventing pneumonia in patients with acute cerebral infarction. Materials and Methods A total of 199 consecutive Japanese patients with noncardioembolic acute cerebral infarction, who visited our hospital from January 2010 to April 2016, were retrospectively assessed by using medical records. We compared changes in the occurrence of pneumonia between cilostazol (n = 127) and noncilostazol (n = 72) groups. Results A total of 76% of patients in the cilostazol group were not administered other antiplatelet drugs. The median duration until cilostazol administration was 5 days (interquartile range = 2-8 days) after the onset of cerebral infarction. A total of 8.0% of the cohort was accompanied by pneumonia. The incidence of pneumonia in the cilostazol group was significantly lower than that in the noncilostazol group (4.7% versus 13.9%, P = .02). Within 30 days after acute cerebral infarction, the presence of neurological deterioration in the cilostazol group tended to be lower compared with the noncilostazol group, but this difference was not significant (5.5% versus 12.5%, P = .08). Conclusions These findings suggest that cilostazol is effective for preventing pneumonia in patients with acute cerebral infarction. The antiplatelet drug cilostazol decreases the risk of ischemic stroke recurrence in patients with chronic cerebral infarction. Additionally, cilostazol reduces the occurrence of pneumonia in these patients. The purpose of this study was to investigate whether cilostazol is effective for preventing pneumonia in patients with acute cerebral infarction. A total of 199 consecutive Japanese patients with noncardioembolic acute cerebral infarction, who visited our hospital from January 2010 to April 2016, were retrospectively assessed by using medical records. We compared changes in the occurrence of pneumonia between cilostazol (n = 127) and noncilostazol (n = 72) groups. A total of 76% of patients in the cilostazol group were not administered other antiplatelet drugs. The median duration until cilostazol administration was 5 days (interquartile range = 2-8 days) after the onset of cerebral infarction. A total of 8.0% of the cohort was accompanied by pneumonia. The incidence of pneumonia in the cilostazol group was significantly lower than that in the noncilostazol group (4.7% versus 13.9%, P = .02). Within 30 days after acute cerebral infarction, the presence of neurological deterioration in the cilostazol group tended to be lower compared with the noncilostazol group, but this difference was not significant (5.5% versus 12.5%, P = .08). These findings suggest that cilostazol is effective for preventing pneumonia in patients with acute cerebral infarction." @default.
• W2800100422 created "2018-05-17" @default.
• W2800100422 creator A5009546157 @default.
• W2800100422 creator A5028433026 @default.
• W2800100422 creator A5039183310 @default.
• W2800100422 creator A5070084910 @default.
• W2800100422 creator A5071978686 @default.
• W2800100422 date "2018-09-01" @default.
• W2800100422 modified "2023-10-03" @default.
• W2800100422 title "Preventive Effect of Cilostazol on Pneumonia in Patients with Acute Cerebral Infarction" @default.
• W2800100422 cites W1541421500 @default.
• W2800100422 cites W1965217904 @default.
• W2800100422 cites W1981331194 @default.
• W2800100422 cites W1984664061 @default.
• W2800100422 cites W2001280008 @default.
• W2800100422 cites W2001806963 @default.
• W2800100422 cites W2014459583 @default.
• W2800100422 cites W2018201092 @default.
• W2800100422 cites W2022327996 @default.
• W2800100422 cites W2023954728 @default.
• W2800100422 cites W2038725133 @default.
• W2800100422 cites W2041283773 @default.
• W2800100422 cites W2052474518 @default.
• W2800100422 cites W2061499928 @default.
• W2800100422 cites W2068096255 @default.
• W2800100422 cites W2069024784 @default.
• W2800100422 cites W2074974933 @default.
• W2800100422 cites W2079056347 @default.
• W2800100422 cites W2080504768 @default.
• W2800100422 cites W2081698307 @default.
• W2800100422 cites W2099884864 @default.
• W2800100422 cites W2108159097 @default.
• W2800100422 cites W2113957486 @default.
• W2800100422 cites W2123393844 @default.
• W2800100422 cites W2133660074 @default.
• W2800100422 cites W2133956375 @default.
• W2800100422 cites W2138595885 @default.
• W2800100422 cites W2139670163 @default.
• W2800100422 cites W2140430950 @default.
• W2800100422 cites W2140906876 @default.
• W2800100422 cites W2181368996 @default.
• W2800100422 cites W2578393525 @default.
• W2800100422 cites W2595414771 @default.
• W2800100422 doi "https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.04.024" @default.
• W2800100422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29759939" @default.
• W2800100422 hasPublicationYear "2018" @default.
• W2800100422 type Work @default.
• W2800100422 sameAs 2800100422 @default.
• W2800100422 citedByCount "12" @default.
• W2800100422 countsByYear W28001004222018 @default.
• W2800100422 countsByYear W28001004222019 @default.
• W2800100422 countsByYear W28001004222020 @default.
• W2800100422 countsByYear W28001004222021 @default.
• W2800100422 countsByYear W28001004222022 @default.
• W2800100422 countsByYear W28001004222023 @default.
• W2800100422 crossrefType "journal-article" @default.
• W2800100422 hasAuthorship W2800100422A5009546157 @default.
• W2800100422 hasAuthorship W2800100422A5028433026 @default.
• W2800100422 hasAuthorship W2800100422A5039183310 @default.
• W2800100422 hasAuthorship W2800100422A5070084910 @default.
• W2800100422 hasAuthorship W2800100422A5071978686 @default.
• W2800100422 hasConcept C119060515 @default.
• W2800100422 hasConcept C126322002 @default.
• W2800100422 hasConcept C127413603 @default.
• W2800100422 hasConcept C164705383 @default.
• W2800100422 hasConcept C2777628954 @default.
• W2800100422 hasConcept C2777798775 @default.
• W2800100422 hasConcept C2777914695 @default.
• W2800100422 hasConcept C2779450755 @default.
• W2800100422 hasConcept C2779820409 @default.
• W2800100422 hasConcept C2780645631 @default.
• W2800100422 hasConcept C42219234 @default.
• W2800100422 hasConcept C500558357 @default.
• W2800100422 hasConcept C541997718 @default.
• W2800100422 hasConcept C71924100 @default.
• W2800100422 hasConcept C78519656 @default.
• W2800100422 hasConceptScore W2800100422C119060515 @default.
• W2800100422 hasConceptScore W2800100422C126322002 @default.
• W2800100422 hasConceptScore W2800100422C127413603 @default.
• W2800100422 hasConceptScore W2800100422C164705383 @default.
• W2800100422 hasConceptScore W2800100422C2777628954 @default.
• W2800100422 hasConceptScore W2800100422C2777798775 @default.
• W2800100422 hasConceptScore W2800100422C2777914695 @default.
• W2800100422 hasConceptScore W2800100422C2779450755 @default.
• W2800100422 hasConceptScore W2800100422C2779820409 @default.
• W2800100422 hasConceptScore W2800100422C2780645631 @default.
• W2800100422 hasConceptScore W2800100422C42219234 @default.
• W2800100422 hasConceptScore W2800100422C500558357 @default.
• W2800100422 hasConceptScore W2800100422C541997718 @default.
• W2800100422 hasConceptScore W2800100422C71924100 @default.
• W2800100422 hasConceptScore W2800100422C78519656 @default.
• W2800100422 hasIssue "9" @default.
• W2800100422 hasLocation W28001004221 @default.
• W2800100422 hasLocation W28001004222 @default.
• W2800100422 hasOpenAccess W2800100422 @default.
• W2800100422 hasPrimaryLocation W28001004221 @default.
• W2800100422 hasRelatedWork W1507372118 @default.
• W2800100422 hasRelatedWork W1993761978 @default.

• next